Patents by Inventor John S. Kovach

John S. Kovach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210275521
    Abstract: The present invention relates to compounds and methods useful for treating secondary acute myeloid leukemia (sAML).
    Type: Application
    Filed: December 5, 2018
    Publication date: September 9, 2021
    Inventor: John S. KOVACH
  • Publication number: 20200325151
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: February 5, 2020
    Publication date: October 15, 2020
    Inventors: John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
  • Publication number: 20200179375
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: December 6, 2019
    Publication date: June 11, 2020
    Inventors: John S. Kovach, Mickey L. Wells
  • Patent number: 10668062
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 2, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Patent number: 10618908
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Publication number: 20200069680
    Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Inventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
  • Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • Publication number: 20190359627
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: June 12, 2019
    Publication date: November 28, 2019
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10434100
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 8, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Patent number: 10413541
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 17, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Salvatore Lecca, Manuel Mameli
  • Patent number: 10399993
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: September 3, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • Patent number: 10364252
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 30, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Publication number: 20190167671
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
    Type: Application
    Filed: November 30, 2018
    Publication date: June 6, 2019
    Inventor: John S. Kovach
  • Publication number: 20190111053
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure (I) or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 18, 2019
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20190046525
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 14, 2019
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20180370983
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: June 26, 2018
    Publication date: December 27, 2018
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. KOVACH, Francis JOHNSON
  • Patent number: 10149847
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 11, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Publication number: 20180256565
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Application
    Filed: November 17, 2017
    Publication date: September 13, 2018
    Inventors: John S. Kovach, Salvatore Lecca, Manuel Mameli
  • Patent number: 10071094
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: September 11, 2018
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20180244690
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat